Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer

Surgery ◽  
2014 ◽  
Vol 155 (3) ◽  
pp. 408-416 ◽  
Author(s):  
Bang Wool Eom ◽  
Jungnam Joo ◽  
Young-Woo Kim ◽  
Daniel Reim ◽  
Ji Yeon Park ◽  
...  
2011 ◽  
Vol 98 (5) ◽  
pp. 667-672 ◽  
Author(s):  
J. Y. An ◽  
K. H. Pak ◽  
K. Inaba ◽  
J.-H. Cheong ◽  
W. J. Hyung ◽  
...  

2008 ◽  
Vol 25 (5) ◽  
pp. 351-358 ◽  
Author(s):  
Taka-aki Masuda ◽  
Yoshihisa Sakaguchi ◽  
Yasushi Toh ◽  
Yoshiro Aoki ◽  
Norifumi Harimoto ◽  
...  

2021 ◽  
Author(s):  
Xing Xu ◽  
Guoliang Zheng ◽  
Tao Zhang ◽  
Yan Zhao ◽  
Zhichao Zheng

Abstract Background: The validity of lymphadenectomy of the lymph node along the superior mesenteric vein (LN14v) in gastric cancer remains controversial. The study investigated the characteristics and prognosis of gastric cancer with metastasis or micrometastasis to LN14v.Methods: A retrospective study of 626 patients receiving radical gastrectomy in our center from January 2003 to December 2015 was analyzed. Totally, 303 patients receiving lymphadenectomy of 14v and lymph node micrometastasis was evaluated by immunohistochemical staining for cytokeratinnodes CK8/18. Logistic regression model was applied to confirm the predictive factors of micrometastasis. Survival analysis was performed to evaluate the effect of micrometastasis or metastasis on prognosis.Results: The metastastic rate of No.14v lymph node was 15.8% and the micrometastatic rate was 3.9%. Multivariate analysis showed site, Borrmann classification, postoperative lymph node metastasis (pN), the metastasis of LN6 and LN9 were predictive factors of LN14v micrometastasis or metastaticsis (P<0.05). The 5-year survival rate of positive group (14v micrometastasis or metastasis) was 12.4%. The prognosis of patients without micrometastatic 14v lymph node was better than positive group. While the difference between group of LN14v micrometastasis and LN14v metastasis was not obvious. In matched analysis, patients with gastric cancer of stage Ⅲ, U/M area, pN2-3 and LN 6(+) underwent lymphadenectomy of 14v suffered better survival than those without lymphadenectomy of 14v. Conclusion: Lymph node micrometastasis could provide accurate prognostic information for patients with GC. Thus, lymphadenectomy of LN14v should be recommended for patients with gastric cancer of stage Ⅲ, U/M area, pN2-3 and LN 6(+).


2021 ◽  
Vol 11 ◽  
Author(s):  
Xing Xu ◽  
Guoliang Zheng ◽  
Tao Zhang ◽  
Yan Zhao ◽  
Zhichao Zheng

BackgroundThe validity of lymphadenectomy of the lymph node along the superior mesenteric vein (LN14v) in gastric cancer remains controversial. The study investigated the characteristics and prognosis of gastric cancer with metastasis or micrometastasis to LN14v.MethodsA retrospective study of 626 patients undergoing radical gastrectomy in our center from January 2003 to December 2015 was analyzed. In total, 303 patients had lymphadenectomy of LN14v, and lymph node micrometastasis was evaluated by immunohistochemical staining for cytokeratin nodes CK8/18. A logistic regression model was applied to confirm the predictive factors of micrometastasis. Survival analysis was performed to evaluate the effect of micrometastasis or metastasis on prognosis.ResultsThe metastatic rate of the LN14v lymph node was 15.8%, and the micrometastatic rate was 3.3%. Multivariate analysis showed site, Borrmann classification, postoperative lymph node metastasis (pN), and metastasis in LN6 and LN9 were predictive factors for LN14v micrometastasis or metastasis (P &lt; 0.05). The 5-year survival rate in the positive group (LN14v micrometastasis or metastasis) was 12.4%. The prognosis of patients without LN14v lymph node micrometastasis was better than that of the positive group, whereas the difference between group of LN14v micrometastasis and LN14v metastasis was not obvious. In matched analysis, patients with stage III gastric cancer L/M area, pN2-3, and LN6(+) who underwent lymphadenectomy of LN14v had better survival than those without lymphadenectomy of LN14v.ConclusionLymph node micrometastasis may provide accurate prognostic information for patients with gastric cancer. Moreover, lymphadenectomy of LN14v might improve the survival of patients with stage III gastric cancer of L/M area, pN2-3, and LN6(+).


Author(s):  
Kaja Ludwig ◽  
Sylke Schneider-Koriath ◽  
Uwe Scharlau ◽  
Holger Steffen ◽  
Daniela Möller ◽  
...  

Abstract Background Laparoscopic gastrectomy has been established for treatment of early gastric cancer (EGC) especially in Eastern Asian countries. Currently, it still needs evaluation for advanced gastric cancer (AGC, T ≥ 2). Difficulty is how far Asian study data are valid for western conditions. Methods Out of 502 patients who underwent gastric cancer surgery between 2003 and 2016 at Klinikum Suedstadt Rostock 90 patients were selected for a retrospective study to compare totally laparoscopic D2-gastrectomy (LG, n = 45) with open D2-gastrectomy (OG, n = 45). The groups were matched by age, gender and tumour stage (TNM). Results Average age was 62.9 years (33 – 83), 42.2% were female. There were no differences between both study groups concerning BMI, ECOG and comorbidities. Amounts of EGC and AGC were 35.5% and 64.4% in LG, 28.9% and 71.0% in OG (p = 0.931). In LG-group 53.3% of the patients and in OG-group 51.1% of the patients were nodal negative (p = 0.802). 31.1% of patients in LG and in 33.3% in OG (p = 0.821) undergone perioperative chemotherapy. Total gastrectomy was performed in 73.3% in LG and 82.2% in OG, subtotal resections were done in 26.7% in LG and 17.8% in OG (p = 0.310). Resection free margins (R0) were recognized in 97.8% of the patients in both groups, and for EGC in all cases (p = 0.928). Total numbers of retrieved lymph nodes were significant higher in LG (33.1, 17 – 72) than in OG (28.2, 14 – 57). A significant longer operation time was noticed for laparoscopic gastrectomy in contrast to open surgery (+ 43.0 ± 27.2 min, p = 0.0054). Overall morbidity in OG (44.4%) was twice as high as in LG (22.2%, p < 0.05) due to lower rate of minor complications (Clavien I – II) in LG (LG vs. OG: 13.3% vs. 37.8%, p = 0.0078). For major complications (Clavien ≥ III) no difference between both groups was detected (LG vs. OG: 8.8% vs. 6.6%, p = 0.69). LG showed a significant faster postoperative recovery with earlier oral fluid intake (LG vs. OG: 25.9 h vs. 46.2 h) and shorter time to first flatus (LG vs. OG: 81.6 vs. 102.6 h). Patients after LG were earlier out of bed (LG vs. OG: 69.7 h vs. 108.7 h) and also hospital stay was significantly shorter (11.9 days in LG vs. 16.3 days in OG, p = 0.037). 30- and 90-days mortality was equal for LG and OG (0 and 2.2% per group). After a median follow up of 51.9 month (1 – 117) there were similar results for 3- and 5-year overall survival (OS for LG: 75.6% and 64.6% vs. OG: 68.9% and 64.6%, p = 0.446). Also no differences for 3- and 5-year OS were detected concerning patients without lymph node metastases (LG: 91.7% and 83.4% vs. OG: 91.3% and 78.3%, p = 0.658) or lymph node positive patients (LG: 47.6% and 38.1% vs. OG: 40.9% and 31.8%, p = 0.665). Conclusion Despite western conditions laparoscopic D2 gastrectomy is certainly a save and feasibly approach for surgical therapy of EGC and AGC with low morbidity and mortality, and faster postoperative recovery. The oncologic outcome seems to be equivalent to open surgery.


Sign in / Sign up

Export Citation Format

Share Document